Abstract
Results from two phase III trials show the potency of alemtuzumab—a T-cell and B-cell depleting antibody—in reducing clinical and paraclinical measures of disease activity in relapsing–remitting multiple sclerosis. The effects of this immunotherapeutic agent highlight the relevance of T lymphocytes in the early pathogenesis of disease.
MeSH terms
-
Alemtuzumab
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antigens, CD / immunology
-
Antigens, Neoplasm / immunology
-
CD52 Antigen
-
Clinical Trials, Phase III as Topic
-
Glycoproteins / immunology
-
Humans
-
Multiple Sclerosis / immunology*
-
Multiple Sclerosis / therapy*
Substances
-
Antibodies, Monoclonal, Humanized
-
Antigens, CD
-
Antigens, Neoplasm
-
CD52 Antigen
-
CD52 protein, human
-
Glycoproteins
-
Alemtuzumab